10. October 2017

Looking at affordability and patient-recorded outcomes, the panel will address the future of immuno-X therapies, therapy experiences and drug interactions, as well as patient-centric dosage forms and medical devices, with a focus on patient centricity driven and enabled by end users: patients and healthcare providers in an R&D partnership.